Liquidia Technologies is a company that maintains the mission of developing and changing how drugs and therapies are engineered. The company was founded in 2004, in Morrisville, North Carolina, United States.
The company has developed a proprietary technology named PRINT, which allows users to solve problems they may face in drug delivery and efficacy. The technology hold a scalable cGMP process that creates particle that can be applied to any therapeutic or point of administration.
PRINT allows for particle engineering platforms to provide control over drug particle size, shape, and chemical composition. This allows their users to selectively create their desired pharmacological effects such as time of drug release, amount of drug loading, route of administration, and novel storage and combination of products.
The platform allows for particle molding and allows users to deliver scalable processes that meet cGMP requirements. The technology is also a solution for semi-conductor markets as PRINT allows for the manufacturing of uniform particles at a commercially viable scale.
Michele Stone, Ph.D., PMP